Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India

Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India

Introduction: Severe Haemophilia A patients with inhibitors are currently being treated with bypassing agents like activated prothrombin complex concentrates (aPCC) and recombinant factor VIIa. Emicizumab is a recombinant humanized monoclonal antibody, introduced to reduce the bleeding events, impro...

Full description

Bibliographic Details
Main Authors: Yuvaraj Krishnamoorthy, Dhanajayan Govindan, Narasimhapriyan Kannan, Marie Gilbert Majella, Vishnu Shankar Hariharan, Vivek Valliappan
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Heliyon
Subjects:
Cost utility analysis
Emicizumab
Haemophilia A
India
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024031207

Similar Items

Similar Items